Sanofi successfully prices EUR 750 million bond issue

PR Newswire/Les Echos/ 
   Sanofi successfully prices EUR 750 million bond issue 
Paris, France - November 7, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY)
announces today that it has successfully priced its offering of EUR 750 million
of notes, due 2017, bearing interest at an annual rate of 1 %. 
The issue is made under the Company's Euro Medium Term Note Programme. 
Sanofi intends to use the net proceeds of the offering for general corporate
purposes, including the repayment of existing borrowings. 
BNP Paribas, Credit Agricole CIB, HSBC and Mitsubishi UFJ Securities
International Plc acted as joint bookrunning managers for the offering. 
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris 
(EURONEXT: SAN) and in New York (NYSE: SNY). 
Not for distribution in the United States 
This communication shall not constitute an offer to sell or the solicitation of
an offer to buy nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state or
This communication is only being distributed to and is only directed at (i)
persons who are outside the United Kingdom or (ii) investment professionals
falling within Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order") or (iii) high net worth
companies, and other persons to whom it may lawfully be communicated, falling
within Article 49(2)(a) to (d) of the Order or (iv) persons to whom an
invitation or inducement to engage in investment activity (within the meaning 
of section 21 of the FSMA, as defined below) may otherwise lawfully be 
communicated or cause to be communicated (all such persons together being 
referred to as "relevant persons"). The notes are only available to, and any 
invitation, offer or agreement to subscribe, purchase or otherwise acquire such
notes will be engaged in only with, relevant persons. Any person who is not a 
relevant person should not act or rely on this document or any of its contents. 
No prospectus (including any amendment, supplement or replacement thereto) or
any other offering material has been prepared in connection with the offering 
of the notes that has been approved by the Autorité des marchés financiers or 
by the competent authority of another State that is a contracting party to the
Agreement on the European Economic Area and notified to the Autorité des
marchés financiers; no notes have been offered or sold nor will be offered or
sold, directly or indirectly, to the public in France; the prospectus or any
other offering material relating to the notes have not been distributed or
caused to be distributed and will not be distributed or caused to be 
distributed to the public in France; such offers, sales and distributions have 
been and shall only be made in France to persons licensed to provide the 
investment service of portfolio management for the account of third parties or 
to qualified investors (investisseurs qualifiés) other than individuals, in 
each case investing for their own account, all as defined in Articles L. 411-2,
D. 411-1 to D. 411-3, D. 734-1, D. 744-1, D. 754-1 and D. 764-1 of the French 
Code monétaire et financier. The direct or indirect distribution to the public 
in France of any so acquired notes may be made only as pro vided by Articles 
L. 411-1, L. 411-2, L. 412-1 and L. 621-8 to L. 621-8-3 of the French Code
monétaire et financier and applicable regulations thereunder. 
Forward-Looking Statements
Any statements made in this communication that are not statements of historical
fact, including statements about Sanofi's beliefs and expectations are
forward-looking statements and should be evaluated as such. Forward-looking
statements include statements that may relate to Sanofi's plans, objectives,
strategies, goals, future events, future revenues or performance, and other
information that is not historical information. Sanofi does not undertake, 
and specifically disclaims, any obligation or responsibility to update or amend 
any of the information above except as otherwise required by law. 
Additional Information:
This communication is neither an offer to purchase nor a solicitation of any
offer to sell any securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such
Media Relations                 Investor Relations
Jean-Marc Podvin                Sébastien Martel
Tel.: + (33) 1 53 77 46 46      Tel.: + (33) 1 53 77 45 45          
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Nov/07/2012 14:23 GMT
Press spacebar to pause and continue. Press esc to stop.